Analyst John Newman of Canaccord Genuity maintained a Buy rating on Candel Therapeutics (CADL – Research Report), retaining the price target of $25.00.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
John Newman’s rating is based on several promising developments within Candel Therapeutics’ pipeline. The company’s CAN-2409, a treatment for prostate cancer, has shown significant efficacy in reducing the risk of recurrence or death in patients, with a high complete response rate compared to the control group. This treatment is on track for a Biologics License Application (BLA) submission in the fourth quarter of 2026, and the data supporting this submission is strong, increasing the likelihood of approval.
Additionally, the upcoming presentation of Phase 3 data for CAN-2409 at the American Society of Clinical Oncology (ASCO) conference is expected to enhance interest among oncologists, further supporting the stock’s potential. Moreover, Candel’s CAN-3110, targeting recurrent high-grade glioma, has demonstrated promising survival data, with further results anticipated in late 2025. These factors collectively underscore the long-term value potential of Candel’s offerings, justifying the Buy rating and a price target of $25.
Newman covers the Healthcare sector, focusing on stocks such as Candel Therapeutics, Adicet Bio, and BioNTech SE. According to TipRanks, Newman has an average return of -6.6% and a 30.92% success rate on recommended stocks.
In another report released yesterday, Bank of America Securities also reiterated a Buy rating on the stock with a $15.00 price target.